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Prevalence and Predictors of Postdischarge Antibiotic
Use Following Mastectomy
Margaret A. Olsen, PhD, MPH;1,2 Katelin B. Nickel, MPH;1 Victoria J. Fraser, MD;1 Anna E. Wallace, MPH;3
David K. Warren, MD, MPH1
objective. Survey results suggest that prolonged administration of prophylactic antibiotics is common after mastectomy with
reconstruction. We determined utilization, predictors, and outcomes of postdischarge prophylactic antibiotics after mastectomy with or without
immediate breast reconstruction.
design. Retrospective cohort.
patients. Commercially insured women aged 18–64 years coded for mastectomy from January 2004 to December 2011 were included in the
study. Women with a preexisting wound complication or septicemia were excluded.
methods. Predictors of prophylactic antibiotics within 5 days after discharge were identiﬁed in women with 1 year of prior insurance
enrollment; relative risks (RR) were calculated using generalized estimating equations.
results. Overall, 12,501 mastectomy procedures were identiﬁed; immediate reconstruction was performed in 7,912 of these procedures
(63.3%). Postdischarge prophylactic antibiotics were used in 4,439 procedures (56.1%) with immediate reconstruction and 1,053 procedures
(22.9%) without immediate reconstruction (P< .001). The antibiotics most commonly prescribed were cephalosporins (75.1%) and ﬂuor-
oquinolones (11.1%). Independent predictors of postdischarge antibiotics were implant reconstruction (RR, 2.41; 95% conﬁdence interval [CI],
2.23–2.60), autologous reconstruction (RR, 2.17; 95% CI, 1.93–2.45), autologous reconstruction plus implant (RR, 2.11; 95% CI, 1.92–2.31),
hypertension (RR, 1.05; 95% CI, 1.00–1.10), tobacco use (RR, 1.07; 95% CI, 1.01–1.14), surgery at an academic hospital (RR, 1.14; 95% CI,
1.07–1.21), and receipt of home health care (RR, 1.11; 95% CI, 1.04–1.18). Postdischarge prophylactic antibiotics were not associated with SSI
after mastectomy with or without immediate reconstruction (both P> .05).
conclusions. Prophylactic postdischarge antibiotics are commonly prescribed after mastectomy; immediate reconstruction is the strongest
predictor. Stewardship efforts in this population to limit continuation of prophylactic antibiotics after discharge are needed to limit
antimicrobial resistance.
Infect Control Hosp Epidemiol 2017;1–7
Surgical-site infections (SSIs) are the most common
healthcare-associated infections in the United States; an
estimated 157,500 SSIs occur annually.1 The Centers for
Disease Control and Prevention (CDC) guidelines for the
prevention of SSI recommend the use of preoperative anti-
biotic prophylaxis for procedures for which data support the
beneﬁt of prophylactic antibiotics, for those that involve
implantation of a medical device, or in surgeries in which an
SSI is potentially catastrophic.2 The most recent CDC guide-
lines recommend against administration of prophylactic anti-
biotics in clean surgeries after the surgical incision is closed,
even in the presence of surgical drains,3 due to lack of data
showing beneﬁt with this practice. Other national and
international organizations recommend stopping prophylactic
antibiotics within 24 hours of noncardiothoracic surgery.2,4,5
In practice, compliance with limiting the duration of
prophylactic antibiotic after surgery varied by 58%–100% in a
study of National Surgical Quality Improvement Program
hospitals.6,7 A major concern with the use of postdischarge
antibiotic prophylaxis is exposing patients to unnecessary
antibiotics. The use of unnecessary antibiotics may result
in additional costs and adverse events in addition to selection
of antibiotic-resistant bacteria8 and Clostridium difﬁcile
infection.9
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Postdischarge antibiotic prophylaxis use is common in
mastectomy10–13 and breast augmentation,14,15 after which
surgeons often continue antibiotics until removal of all surgi-
cal drains. The American Society of Plastic Surgeons practice
guidelines for expander/implant breast reconstruction
recommend that antibiotics be discontinued <24 hours after
surgery unless drains are present, in which case prophylaxis
duration is left to surgeon preference.16 In a survey of 460
plastic surgeons, 72% prescribed outpatient antibiotics after
mastectomy with breast reconstruction.17 Another survey of
253 plastic surgeons who performed primarily cosmetic breast
augmentation reported that 84% prescribed postoperative
antibiotics, with 73% continuing them for >3 days.18
We utilized a large commercial health insurer database to
analyze use and outcomes of postdischarge prophylactic anti-
biotics in a cohort of women undergoing mastectomy with and
without immediate reconstruction. We aimed to determine
the prevalence of postdischarge prophylactic antibiotics in
uncomplicated procedures, to identify patient and operative
factors associated with this utilization, and in a secondary
analysis, to determine whether postdischarge antibiotic use
was associated with decreases in SSI and noninfectious wound
complications (NIWCs). The use of large generalizable health
insurer claims data allowed for better understanding of
practice regarding continuation of prophylactic antibiotics
after hospital discharge among a wide variety of surgeons and
potential stewardship opportunities to limit this practice in
breast surgery. Unlike previous studies, the large database also
provided the statistical power to determine the association of
postdischarge antibiotics and the incident SSIs and NIWCs.
methods
Primary Data Source
We conducted a retrospective cohort study using all fully
adjudicated, paid claims submitted for reimbursement from
providers, facilities, and outpatient pharmacies linked to
health plan enrollment information from 12 Anthem-afﬁliated
plans in the HealthCore Integrated Research Database (Online
Supplemental Appendix).19 Fully insured women with
enrollment in a fee-for-service plan with medical coverage of
hospital and physician services and prescription drug coverage
were eligible for inclusion in the cohort. Women with end-
stage renal disease, prior organ transplant, or HIV infection
were excluded due to the rare nature of the conditions and for
privacy concerns.
Mastectomy Population
We identiﬁed inpatient mastectomy operations among insured
members aged 18–64 years from January 1, 2004, to December
31, 2011, using the International Classiﬁcation of Diseases, 9th
Revision, Clinical Modiﬁcation (ICD-9-CM) and Current
Procedural Terminology, 4th edition (CPT-4) procedure codes
from facilities and providers, as described previously.19
Classiﬁcation of the mastectomy and reconstruction has been
described in detail.19,20 To limit the identiﬁcation of antibiotics
to those prescribed for prophylaxis (rather than therapeutic
indications), we excluded operations for which SSI,19
cellulitis,19 NIWCs,21 port infection (ICD-9-CM diagnosis
996.62), or septicemia (ICD-9-CM diagnosis 038.0–038.9,
790.7) were coded from 30 days before mastectomy through
5 days after discharge from the mastectomy hospitalization.
Postdischarge Prophylactic Antibiotics
We deﬁned postdischarge prophylactic antibiotics as any of the
following antibiotics from paid claims in the outpatient pharmacy
ﬁle from 0 to 5 days after mastectomy discharge: cephalosporins,
ﬂuoroquinolones, lincosamides, macrolides, penicillins, rifampin,
sulfamethoxazole-trimethoprim, and tetracyclines.
Predictors of Prophylactic Antibiotic Use
To identify predictors of postdischarge prophylactic antibiotic
use in univariate and multivariable analyses, we limited the
population to (1) women with insurance coverage 365 days
before surgery through 30 days after surgery, (2) the ﬁrst
mastectomy per patient, and (3) records without missing
information on patient region of residence (Appendix ﬁgure).
Potential predictors of prophylactic antibiotic use included
demographics, comorbidities (primarily using the Elixhauser
classiﬁcation),22 medications, cancer, operative factors, and
facility factors with clinical or biologic plausibility for asso-
ciation with antibiotic use and/or risk for SSI, as described
previously.20,21 We included postoperative home health care
within 10 days after discharge unless the home health visits
were ﬁrst coded at the time of or after an SSI or NIWC because
these visits were likely due to wound care.
Complications After Mastectomy
SSIs and NIWCs ﬁrst recorded from 6 days after mastectomy
discharge through 90 days after mastectomy were identiﬁed
using ICD-9-CM diagnosis codes from inpatient and
outpatient facilities and provider claims, as reported pre-
viously.19,21 NIWCs included fat necrosis (567.82, 611.3),
dehiscence (875.0, 875.1, 879.0, 879.1, 998.3, 998.32),
hematoma (998.12), and tissue necrosis (998.83). We censored
the observation period to capture complications before a
subsequent surgical procedure, as described previously.19 We
captured C. difﬁcile infection (ICD-9-CM diagnosis code
008.45 or prescription for oral vancomycin) through 30 days
after discharge from the mastectomy hospitalization. For
persons with prophylactic antibiotic use, we only included
C. difﬁcile coded on or after the ﬁrst postdischarge antibiotic date.
Statistical Analyses
We determined potential predictors of prophylactic antibiotic
use using χ2 tests for binary variables and a generalized
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estimating equations (GEE) model for multicategory variables.
Any predictors with a cell size <5 were excluded from analysis.
Among factors with P< .2 in univariate analysis, we assessed
multicollinearity by examining the tolerance values in each
model to ensure independence of explanatory variables. A GEE
model was used to estimate adjusted relative risks because the
prevalence of prophylactic antibiotics was high. Backward
selection was used with a cutoff of P< .05. For our secondary
aim, we compared the incidence of SSI and NIWCs after
mastectomy according to prophylactic antibiotic use with a
logistic regression model, controlling for type of breast
reconstruction. All data management and analyses were
performed using SAS version 9.4 software (SAS Institute, Cary,
NC). We performed post hoc power calculations using PASS
14 Power Analysis and Sample Size Software (NCSS, LLC,
Kaysville, UT). This study was approved by the Washington
University Human Research Protection Ofﬁce.
results
Starting with our previously described population of 18,696
mastectomy procedures,19 12,501 inpatient mastectomy
procedures among 12,198 patients with medical and pre-
scription drug coverage met eligibility criteria for this study
(Appendix). Immediate reconstruction was performed in
7,912 (63.3%) procedures. Prophylactic antibiotics were
prescribed post discharge after 5,492 (43.9%) procedures
overall. Of 5,651 unique prescriptions within 5 days post
discharge, cephalosporins were the most commonly pre-
scribed antibiotic class (75.1%), followed by ﬂuoroquinolones
(11.1%), lincosamides (4.8%), and penicillins (3.5%).
Utilization of postdischarge prophylactic antibiotics was more
common after mastectomy with immediate reconstruction
than after mastectomy only (4,439 [56.1%] vs 1,053 [22.9%];
P< .001).
Overall, 793 procedures were coded for SSI (6.3%) and 802
(6.4%) were coded for an NIWC within 90 days after surgery.
A total of 13 (0.1%) procedures included evidence for
C. difﬁcile infection within 30 days after hospital discharge. In
mastectomy-only operations, the SSI rates were similar
regardless of postdischarge prophylactic antibiotic use, but the
rate of NIWCs was higher in women given postdischarge
prophylactic antibiotics than in women who did not receive
postdischarge antibiotics (Figure 1). Postdischarge prophy-
lactic antibiotic use was not associated with SSI or NIWCs
following mastectomy with immediate reconstruction
(Figure 1). After adjusting for type of procedure (ie, mas-
tectomy only, implant reconstruction, autologous ﬂap recon-
struction), receipt of postdischarge prophylactic antibiotic
was not associated with SSI (odds ratio [OR], 0.87; 95%
conﬁdence interval [CI], 0.75–1.01) nor NIWCs (OR, 1.14;
95% CI, 0.99–1.33) compared to no prescription for post-
discharge antibiotics. Based on the number of reconstruction
procedures and assuming a 25% reduction in SSI associated
with postdischarge antibiotic use, we achieved 81% power to
detect a difference in the complication rates in the recon-
struction population but much lower power (18%) in the
mastectomy-only population due to the lower percentage
receiving postdischarge antibiotics and the lower baseline
complication rates.
The population for our analysis of risk factors associated
with postdischarge antibiotic utilization was reduced to 9,188
after excluding those with <1 year of prior health insurance
coverage, those with second mastectomy procedures, and 23
procedures with missing US region (Appendix ﬁgure).
In univariate analysis, women who received postdischarge
prophylactic antibiotics were younger, in the higher-income
quartiles, and more likely to have preexisting depression,
tobacco use disorder, skin disease, breast carcinoma in situ or
to be undergoing prophylactic mastectomy than women who
did not receive postdischarge antibiotics (Table 1). Women
who received postdischarge antibiotics were also more likely to
have undergone sentinel node dissection, implant, autologous
ﬂap, and autologous ﬂap plus implant reconstruction, and less
likely to have had a modiﬁed radical mastectomy than women
who did not receive antibiotics post discharge. Several facility
factors were associated with increased likelihood to receive
postdischarge prophylactic antibiotics, including larger bed
size, medical school afﬁliation, residency program, and facility
location in the US Northeast and Midwest regions (Table 1).
The independent predictors of prophylactic antibiotic use
post discharge with the largest effect sizes were operative
factors: immediate breast implant (relative risk [RR], 2.41) and
autologous ﬂap reconstruction with an implant (RR, 2.17)
or without an implant (RR, 2.11). Patient factors (hyperten-
sion, tobacco use disorder, and postoperative home health)
and facility characteristics (surgery at a facility in the Northeast
or Midwest and surgery at an academic hospital) were
ﬁgure 1. Incidence of surgical site infection and noninfectious
wound complications by postdischarge prophylactic antibiotic use
and presence of immediate breast reconstruction (N= 12,501).
NOTE. Abx, antibiotic; NIWC, noninfectious wound complication;
SSI, surgical-site infection.
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associated with slightly increased risk of postdischarge
prophylactic antibiotic use after controlling for the type of
procedure (Table 2).
discussion
We determined variation and predictors of postdischarge
prophylactic antibiotic use in a large population of women
undergoingmastectomy using geographically diverse claims data.
Despite recommendations in many surgical guidelines to dis-
continue administration of prophylactic antibiotics either
immediately after surgery or within 24 hours after a procedure,
antibiotics are frequently overused postoperatively, particularly
after breast operations. We found that utilization of post-
discharge prophylactic antibiotics ranged from 23% for mas-
tectomy without immediate reconstruction to 56% for
mastectomy with immediate reconstruction. These results are in
line with survey data suggesting that plastic surgeons are more
likely to continue patients on prophylactic antibiotics post dis-
charge than general breast surgeons.17,23 Given their common
utilization of antibiotics, surgeons are positioned to be key part-
ners in the success of hospital antibiotic stewardship programs.24
Factors associated with prolonged perioperative prophylaxis
are critical to development of interventions to assure appro-
priate antibiotic use. By far, the most important
predictors of postdischarge prophylactic antibiotics after
mastectomy were autologous ﬂap and implant reconstruction,
which were associated with a 2.1–2.4-fold increased risk of
table 1. Univariate Predictors of Postdischarge Prophylactic
Antibiotics After 9,188 Mastectomy Proceduresa
Postdischarge Prophylactic
Antibiotic Use
Variable Yes, No. (%) No, No. (%) P
Total 4,071 5,117
Patient factors
Age
18–35 years 208 (5.1) 204 (4.0) .59
36–40 years 356 (8.7) 357 (7.0) .68
41–45 years 673 (16.5) 701 (13.7) Ref
46–50 years 913 (22.4) 1,040 (20.3) .20
51–55 years 797 (19.6) 982 (19.2) .02
56–60 years 664 (16.3) 1,035 (20.2) <.001
61–64 years 460 (11.3) 798 (15.6) <.001
Income quartileb
0–25th percentile 797 (19.6) 1,254 (24.5) <.001
26–50th percentile 930 (22.8) 1,224 (23.9) <.001
51–75th percentile 1,036 (25.4) 1,206 (23.6) .06
76–100th percentile 1,176 (28.9) 1,227 (24.0) Ref
Missing 132 (3.2) 206 (4.0) .002
Comorbidities/Medications
Anticoagulopathy drugs 60 (1.5) 107 (2.1) .03
Depression 302 (7.4) 333 (6.5) .09
Diabetes 229 (5.6) 373 (7.3) .001
Hypertension 1,216 (29.9) 1,623 (31.7) .06
Liver disease 13 (0.3) 28 (0.5) .10
Malnutrition/weight loss 35 (0.9) 60 (1.2) .14
Cancer (other than breast) 331 (8.1) 490 (9.6) .02
Obesity 267 (6.6) 373 (7.3) .17
Skin disease 102 (2.5) 103 (2.0) .11
Tobacco use disorder 527 (12.9) 608 (11.9) .12
Smoking-related diseases 107 (2.6) 178 (3.5) .02
Stage of breast cancer
Benign or prophylactic 160 (3.9) 146 (2.9) .003
Carcinoma in situ 585 (14.4) 589 (11.5) <.001
Local 2,465 (60.6) 3,100 (60.6) Ref
Regional 772 (19.0) 1,144 (22.4) .003
Metastatic 89 (2.2) 138 (2.7) .15
Operative factors
Type of procedure
Unilateral mastectomy only 581 (14.3) 1,844 (36.0) Ref
Bilateral mastectomy only 185 (4.5) 640 (12.5) .37
Mastectomy plus implant 2,535 (62.3) 1,878 (36.7) <.001
Mastectomy plus ﬂap 570 (14.0) 562 (11.0) <.001
Mastectomy plus ﬂap and implant 200 (4.9) 193 (3.8) <.001
Modiﬁed radical mastectomy 1,522 (37.4) 2,271 (44.4) <.001
Sentinel node dissection 1,126 (27.7) 1,233 (24.1) <.001
Facility factors
No. of beds
1–299 839 (20.6) 1,354 (26.5) Ref
300–499 881 (21.6) 1,137 (22.2) <.001
500 + 826 (20.3) 838 (16.4) <.001
Missingc 1,525 (37.5) 1,788 (34.9) <.001
Location of facility
Urban 2,460 (60.4) 3,126 (61.1) <.001
Rural 86 (2.1) 203 (4.0) Ref
Missingc 1,525 (37.5) 1,788 (34.9) <.001
Medical school afﬁliation
Yes 1,638 (40.2) 1,777 (34.7) <.001
No 908 (22.3) 1,552 (30.3) Ref
Missingc 1,525 (37.5) 1,788 (34.9) <.001
Residency program
Yes 1,424 (35.0) 1,530 (29.9) <.001
No 1,122 (27.6) 1,799 (35.2) Ref
Missingc 1,525 (37.5) 1,788 (34.9) <.001
Region of facilityd
Northeast 984 (24.2) 830 (16.2) <.001
South 1,174 (28.8) 1,749 (34.2) .58
table 1. Continued
Postdischarge Prophylactic
Antibiotic Use
Variable Yes, No. (%) No, No. (%) P
Midwest 702 (17.2) 786 (15.4) <.001
West 1,211 (29.7) 1,752 (34.2) Ref
Postoperative factors
Home health caree 577 (14.2) 601 (11.7) .001
NOTE. Ref, reference group.
aThe following factors had P ≥ 0.2 and were excluded from the table:
alcohol abuse, blood loss anemia, coagulopathy, collagen vascular/
rheumatologic disease, congestive heart failure, deﬁciency anemia,
disease-modifying anti-rheumatic drugs, oral steroids, peripheral
vascular disease, pneumonia or urinary tract infection within 30 days
prior to surgery, psychoses, renal failure, prior Staphylococcus aureus
infection, inﬂammatory breast disease, history of breast cancer, and
history of radiotherapy.
bBased on median for zip code.
cMissing facility information due to no facility claim for procedure,
no match to a facility in the American Hospital Association Annual
Survey of Hospitals, or a match to multiple facilities.
dFor those with missing facility information, we used patient home
zip code when possible to determine the US region of the facility.
eRestricted to home health care before a surgical site infection or
noninfectious wound complication.
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prolonged antibiotic use. Immediate reconstruction is pre-
ferred over delayed reconstruction by many plastic
surgeons due to better cosmesis and perceived psychosocial
beneﬁts for the patient.25 Surgery performed in a teaching
facility and in facilities located in the US Northeast and
Midwest regions were also associated with a slightly increased
risk of postdischarge prophylactic antibiotic use. This regional
variation in the use of prolonged antibiotics is important to
investigate further because it may have broad implications for
regional differences in antibiotic stewardship programs as well
as rates of antibiotic resistance in the community. In contrast,
patient characteristics were associated with only slightly
increased risk of prolonged antibiotic utilization, suggesting
that stewardship interventions to reduce postdischarge
antibiotic utilization should target primarily plastic surgeons
performing immediate reconstruction.
In addition, 3 prior observational breast surgery studies
reported signiﬁcantly lower SSI rates in patients given post-
discharge prophylactic antibiotics compared to either the
recommended practice of a single dose of antibiotic before
incision26 or prophylaxis limited to 24 hours after surgery.27,28
The study by Edwards et al included procedures performed by
only 2 surgeons, 1 of whom always prescribed postoperative
antibiotics until drains were removed while the other surgeon
never used postoperative antibiotics. Therefore, confounding
bias may be present in this study due to unmeasured differ-
ences in operative technique or other practices between these
2 surgeons.27 In the studies by Clayton et al26 and Avashia
et al,28 retrospective comparisons of SSI rates during time
periods with different prophylactic antibiotic practices were
performed. It is possible that other infection control and
operative practices varied between time periods, resulting in
residual confounding. In the study by Avashia et al,28 a change
in prophylactic antibiotic practice was prompted by a 31.6%
infection rate in 19 women during the period when only
perioperative antibiotics were used, raising the possibility that
the decreased SSI rate after reverting back to prolonged
antibiotic administrative was due to regression to the mean.
The 5 observational studies10,29–32 and 1 randomized trial33
in the literature that did not ﬁnd signiﬁcantly different
SSI rates associated with postdischarge antibiotic use com-
pared to 24 hours or less of antibiotic administration
were small and thus underpowered to detect a signiﬁcant
difference if it existed.34 The lack of high-quality data on the
risk and beneﬁts of postdischarge antibiotic prophylaxis likely
perpetuates the continued use of inappropriate prolonged
antibiotic prophylaxis beyond the recommended 24 hours
of duration.
In contrast to the 3 aforementioned studies that reported
lower SSI rates associated with postdischarge prophylactic
antibiotic use, we found that the rates of SSI and NIWCs did
not differ according to use of postdischarge prophylactic
antibiotics after controlling for procedure type. Importantly,
we had sufﬁcient power (>80%) in the reconstruction
population to detect a difference between postdischarge pro-
phylactic antibiotic use and the incidence of complica-
tions.10,26–33 Cephalosporins were the antibiotic class most
commonly prescribed for postdischarge prophylaxis in our
cohort, followed by ﬂuoroquinolones. Both of these antibiotic
classes are associated with selection for colonization by and
infection with antibiotic-resistant bacteria.35 Fluor-
oquinolones are also increasingly reported to be associated
with serious adverse events.36–38
The coding algorithms we used based on ICD-9-CM and
CPT-4 codes have relatively good sensitivity to identify SSI after
breast procedures39 and C. difﬁcile infection.40 Despite this, our
estimates of SSI, NIWCs, and C. difﬁcile infection rates are
almost certainly underestimates of the true incidence because
the claims algorithm is unlikely to detect most minor infections,
especially during the global 90-day major-surgery reimburse-
ment period. It is possible that not all postdischarge antibiotic
use in the absence of diagnosis codes for infection or NIWCs
represented continuation of antibiotic prophylaxis, although
this is unlikely because our window to identify postdischarge
prophylaxis was very short (within 5 days after discharge).
Outpatient antibiotics were identiﬁed by paid pharmacy
claims; thus, we could not detect antibiotics given as samples or
in the absence of a prescription drug claim, and we could not
conﬁrm that antibiotics were taken as directed. Although
facility characteristics were missing for approximately
one-third of procedures, we think differential misclassiﬁcation
is unlikely, such that certain types of facilities would be dis-
proportionally more or less likely to have a paid claim in the
database or match to the AHA database. We were, however,
able to impute the facility region by using patient zip code,
table 2. Multivariable Predictors of Postdischarge Prophylactic
Antibiotics After Mastectomy Performed During an Inpatient
Hospitalization
Variable
Relative Risk
(95% Conﬁdence Interval)
Hypertension 1.05 (1.00–1.10)
Tobacco use disorder 1.07 (1.01–1.14)
Type of procedure
Unilateral mastectomy only 1.00
Bilateral mastectomy only 0.94 (0.81–1.09)
Mastectomy plus implant 2.41 (2.23–2.60)
Mastectomy plus ﬂap 2.11 (1.92–2.31)
Mastectomy plus ﬂap plus implant 2.17 (1.93–2.45)
Location of facility
West 1.00
Northeast 1.25 (1.18–1.33)
South 1.04 (0.97–1.10)
Midwest 1.19 (1.11–1.28)
Medical school afﬁliation of facility
Yes 1.14 (1.07–1.21)
No 1.00
Missing 1.05 (0.99–1.12)
Home health care 1.11 (1.04–1.18)
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which was important because regional utilization of post-
discharge antibiotics varied.
The strengths of our study include the large population of
women undergoing mastectomy, resulting in sufﬁcient power
to detect differences in complication rates in the reconstruc-
tion population. Our population was enriched in women
undergoing breast reconstruction because of the use of com-
mercial claims data because younger women are more likely to
undergo immediate reconstruction.41 Additional strengths
include the ability to detect regional differences in antibiotic
use because of the broad geographic coverage in the insurer
claims data, and analysis of variation in use of prophylactic
antibiotics by operative, patient, and facility characteristics.
In conclusion, postdischarge prophylactic antibiotic use in the
absence of infectious or noninfectious wound complications is
common after mastectomy, and it is driven primarily by
immediate reconstruction rather than patient-level character-
istics. We found no beneﬁt to continuation of prophylactic
antibiotics post discharge, with similar SSI and NIWC compli-
cation rates in women who received postdischarge antibiotics
versus women who did not receive continued prophylactic
antibiotics. Stewardship efforts to limit the duration of prophy-
lactic antibiotics after surgery and to discourage continuation of
antibiotics after hospital discharge are essential to avoiding
further increases in antimicrobial resistance.
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